US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lakefront Biotherapeutics

29.04

+0.24000.83%

Post-market: 29.040.00000.00%19:30 EDT

Volume:123.46K

Turnover:3.55M

Market Cap:1.91B

PE:2.82

High:29.06

Open:28.66

Low:28.33

Close:28.80

52wk High:37.78

52wk Low:25.68

Shares:65.90M

Float Shares:23.98M

Volume Ratio:0.39

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):10.31

EPS(LYR):5.72

ROE:20.12%

ROA:9.93%

PB:0.50

PE(LYR):5.08

Loading ...

Overview Company News Filings

Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation

Lakefront Biotherapeutics granted orphan drug designation for gamgertamig

Lakefront Biotherapeutics Nv : TD Cowen Reinstates Coverage with Buy Rating

THOMSON REUTERS

Lakefront Biotherapeutics is Maintained at Sector Perform by RBC Capital

RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating

MT Newswires Live

Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating

MT Newswires Live

Lakefront Biotherapeutics NV Reports Results for the Quarter Ended June 30 - Earnings Summary

Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate

Benzinga Earnings

Lakefront Biotherapeutics NV Expected to Post a Loss of €4.64 a Share - Earnings Preview

Earning Preview: Lakefront Biotherapeutics this quarter’s revenue is expected to decrease by 88.74%, and institutional views are constructive

Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley

Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside

Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program

MT Newswires Live

Lakefront Biotherapeutics announces EUR 50M share repurchase program

Lakefront Biotherapeutics Names Eric Hedrick as Chief Medical Officer

MT Newswires Live

Dermatomyositis Trial Update Sets Context For LKFT’s Autoimmune Pipeline

Lakefront Biotherapeutics Spotlight: Completed Phase 2 Lupus Study Sets Stage for Key Data Catalyst

Two new option listings and five option delistings on May 8th

Galapagos NV reports results for the quarter ended March 31 - Earnings Summary

Galapagos Q1 EPS US$0.25 Beats US$(1.27) Estimate, Sales US$7.589M Miss US$16.040M Estimate

Benzinga Earnings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/LKFT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LKFT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LKFT\",,,,,undefined,":{"symbol":"LKFT","market":"US","secType":"STK","nameCN":"Lakefront Biotherapeutics","latestPrice":29.04,"timestamp":1787601600000,"preClose":28.8,"halted":0,"volume":123459,"hourTrading":{"tag":"盘后","latestPrice":29.04,"preClose":29.04,"latestTime":"19:30 EDT","volume":946,"amount":27472.644099999998,"timestamp":1787614204043,"change":0,"changeRate":0,"amplitude":0.000689},"delay":0,"changeRate":0.00833333333333328,"floatShares":23979200,"shares":65897071,"eps":10.306208,"marketStatus":"Post-Mkt","change":0.24,"latestTime":"08-24 19:43:02 EDT","open":28.66,"high":29.06,"low":28.33,"amount":3549853.170864,"amplitude":0.025347,"askPrice":32.48,"askSize":100,"bidPrice":23.17,"bidSize":100,"shortable":3,"etf":0,"ttmEps":10.306208,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"adrRate":1,"listingDate":1431576000000,"exchange":"NASDAQ","adjPreClose":28.8,"preHourTrading":{"tag":"盘前","latestPrice":28.65,"preClose":28.8,"latestTime":"09:29 EDT","volume":1123,"amount":32125.64977,"timestamp":1787578170007,"change":-0.15,"changeRate":-0.005208,"amplitude":0.006944},"postHourTrading":{"tag":"盘后","latestPrice":29.04,"preClose":29.04,"latestTime":"19:30 EDT","volume":946,"amount":27472.644099999998,"timestamp":1787614204043,"change":0,"changeRate":0,"amplitude":0.000689},"volumeRatio":0.390812,"impliedVol":0.449,"impliedVolPercentile":0.8919},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LKFT\",,,,,undefined,":{"symbol":"LKFT","floatShares":23979200,"roa":"9.93%","roe":"20.12%","lyrEps":5.717976,"volumeRatio":0.390812,"shares":65897071,"dividePrice":0,"high":29.06,"amplitude":0.025347,"preClose":28.8,"low":28.33,"week52Low":25.68,"pbRate":"0.50","psRate":"1.66","week52High":37.78,"institutionHeld":0,"latestPrice":29.04,"eps":10.306208,"divideRate":0,"volume":123459,"delay":0,"ttmEps":10.306208,"open":28.66,"prevYearClose":32.7,"prevWeekClose":28.8,"prevMonthClose":27.21,"prevQuarterClose":29.98,"fiveDayClose":27.52,"twentyDayClose":28.13,"sixtyDayClose":28.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LKFT\",params:#limit:5,,,undefined,":[{"date":"2026-08-10","symbol":"LKFT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1786392000000,"name":null,"time":"Post-Mkt","dateTimestamp":1786334400000,"actualEps":null},{"market":"US","date":"2026-05-06","symbol":"LKFT","fiscalQuarterEnding":"2026/03","expectedEps":-1.27,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":0.25},{"date":"2026-02-23","symbol":"LKFT","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":1,"defaultRemindTime":1771880400000,"name":null,"time":"Post-Mkt","dateTimestamp":1771822800000,"actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LKFT","fiscalQuarterEnding":"2025/09","expectedEps":-0.17,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-07-23","symbol":"LKFT","fiscalQuarterEnding":"2025/06","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1753243200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LKFT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LKFT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0.2,"meanLabel":"HOLD","meanPercent":0.6,"analysts":5,"updateTime":1787457600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LKFT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LKFT","date":"2026-08-21","current":2.817719,"percent":0.042857,"low":2.631093,"twenty":3.146693,"median":3.268031,"eighty":3.464868,"high":3.621259,"avg":3.243293,"sd":0.255363,"marketCap":1866440976.41},"quantilePoints":[{"date":"2026-05-15","current":3.154783,"twenty":3.153704,"median":3.154783,"eighty":3.214103,"marketCap":1799919996.5},{"date":"2026-05-22","current":3.203318,"twenty":3.140222,"median":3.161524,"eighty":3.209789,"marketCap":1814059096.28},{"date":"2026-05-29","current":3.297692,"twenty":3.152626,"median":3.204666,"eighty":3.248617,"marketCap":1878385218.51},{"date":"2026-06-05","current":3.289602,"twenty":3.154783,"median":3.206014,"eighty":3.248617,"marketCap":1869203129.5},{"date":"2026-06-12","current":3.362405,"twenty":3.156401,"median":3.219496,"eighty":3.286367,"marketCap":1893838384.42},{"date":"2026-06-18","current":3.31387,"twenty":3.161793,"median":3.24646,"eighty":3.307399,"marketCap":1859003793.18},{"date":"2026-06-26","current":3.464868,"twenty":3.177972,"median":3.251853,"eighty":3.357012,"marketCap":1927999458.11},{"date":"2026-07-02","current":3.551153,"twenty":3.194689,"median":3.268031,"eighty":3.402851,"marketCap":1986414339.67},{"date":"2026-07-10","current":3.548456,"twenty":3.203857,"median":3.293647,"eighty":3.464868,"marketCap":1982637069.04},{"date":"2026-07-17","current":3.505314,"twenty":3.206553,"median":3.31387,"eighty":3.504775,"marketCap":1960100498.8},{"date":"2026-07-24","current":3.303084,"twenty":3.209789,"median":3.339486,"eighty":3.496686,"marketCap":1835677361},{"date":"2026-07-31","current":3.2168,"twenty":3.214103,"median":3.321959,"eighty":3.472957,"marketCap":1810159007.6},{"date":"2026-08-07","current":3.146693,"twenty":3.192532,"median":3.308477,"eighty":3.472957,"marketCap":1772341135.05},{"date":"2026-08-14","current":2.63993,"twenty":3.157479,"median":3.293647,"eighty":3.464868,"marketCap":1816958924.78},{"date":"2026-08-21","current":2.678428,"twenty":3.146693,"median":3.268031,"eighty":3.464868,"marketCap":1866440976.41}],"updateTime":1787614982151},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LKFT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662646206","title":"Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662646206","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662646206?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:28","pubTimestamp":1787603280,"startTime":"0","endTime":"0","summary":"A Lakefront Biotherapeutics treatment for the autoimmune disorder pemphigus received orphan drug designation from the Food and Drug Administration.The treatment, gamgertamig, is being developed in col","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","LKFT","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206528","title":"Lakefront Biotherapeutics granted orphan drug designation for gamgertamig","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206528","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206528?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602240,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of pemphigus. Gamgertam...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakefront-biotherapeutics-granted-orphan-drug-designation-for-gamgertamig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakefront-biotherapeutics-granted-orphan-drug-designation-for-gamgertamig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBP","BK4588","LABU","LKFT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661251758","title":"Lakefront Biotherapeutics Nv : TD Cowen Reinstates Coverage with Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2661251758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661251758?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:10","pubTimestamp":1787285458,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1LM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911185","title":"Lakefront Biotherapeutics is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911185?lang=en_us&edition=fundamental","pubTime":"2026-08-11 23:30","pubTimestamp":1786462200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LKFT/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930573.SGD","LU0310800379.SGD","LKFT","LU0708994859.HKD","BK4207","LU0128525929.USD","BK4139","LU0029864427.USD","GSIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994603","title":"RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994603","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994603?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:53","pubTimestamp":1786445611,"startTime":"0","endTime":"0","summary":"RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658961389","title":"Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658961389","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658961389?lang=en_us&edition=fundamental","pubTime":"2026-08-11 17:31","pubTimestamp":1786440710,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics (LKFT) has an average rating of hold and mean price target of $31.96, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658954196","title":"Lakefront Biotherapeutics NV Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658954196","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658954196?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:03","pubTimestamp":1786395818,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics NV reports results for the quarter ended June 30 - Earnings SummaryLakefront Biotherapeutics NVLKFT.OQreported a quarterly adjusted loss of 46 cents per share for the quarter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44720Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658195130","title":"Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658195130","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658195130?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:27","pubTimestamp":1786393678,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics (NASDAQ:LKFT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(13.52) by 102.14 percent. This is a 120 percent increase over losses of $(1.45) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61093364/lakefront-biotherapeutics-q2-eps-0-29-beats-13-52-estimate-sales-21-624m-beat-7-210m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LKFT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657621062","title":"Lakefront Biotherapeutics NV Expected to Post a Loss of €4.64 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657621062","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657621062?lang=en_us&edition=fundamental","pubTime":"2026-08-08 07:18","pubTimestamp":1786144686,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics NV <LKFT.OQ> expected to post a loss of 4.64 a share - Earnings PreviewLakefront Biotherapeutics NVLKFT.OQ,LKFT.Ois expected to  show a fall in quarterly revenue when it repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442PS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LKFT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100761841","title":"Earning Preview: Lakefront Biotherapeutics this quarter’s revenue is expected to decrease by 88.74%, and institutional views are constructive","url":"https://stock-news.laohu8.com/highlight/detail?id=1100761841","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100761841?lang=en_us&edition=fundamental","pubTime":"2026-08-03 10:28","pubTimestamp":1785724122,"startTime":"0","endTime":"0","summary":"Abstract Lakefront Biotherapeutics will report quarterly results on August 10, 2026 Post-Mkt; investors will parse a forecast calling for revenue of 7.95 million euros, negative EPS, and a deep...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Earning Preview: Lakefront Biotherapeutics this quarter’s revenue is expected to decrease by 88.74%, and institutional views are constructive","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650218930","title":"Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650218930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650218930?lang=en_us&edition=fundamental","pubTime":"2026-07-10 17:30","pubTimestamp":1783675811,"startTime":"0","endTime":"0","summary":"Morgan Stanley resumed coverage of Lakefront Biotherapeutics (LKFT) with an Equal Weight rating and $30 price target after the recent closing of th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakefront-biotherapeutics-resumed-with-an-equal-weight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakefront-biotherapeutics-resumed-with-an-equal-weight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650189555","title":"Judah Frommer Maintains Hold on LKFT, Citing Early but Strategic Gamgertamig Acquisition and Limited Economic Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2650189555","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650189555?lang=en_us&edition=fundamental","pubTime":"2026-07-10 17:25","pubTimestamp":1783675525,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer maintained a Hold rating on Lakefront Biotherapeutics today and set a price target of $30.00. Judah Frommer ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/judah-frommer-maintains-hold-on-lkft-citing-early-but-strategic-gamgertamig-acquisition-and-limited-economic-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/judah-frommer-maintains-hold-on-lkft-citing-early-but-strategic-gamgertamig-acquisition-and-limited-economic-upside-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642497562","title":"Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642497562","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642497562?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:18","pubTimestamp":1781036296,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics  said Tuesday it has launched a share repurchase program of up to 50 million Euros, with repurchases to be conducted in the open market through December 31.The program is being executed with Morgan Stanley as counterparty, the company said.The buyback forms part of a broader authorization of up to $150 million in share repurchases tied to the company's transaction with Gilead, announced in March 2026, CFO Aaron Cox said.Lakefront said it may suspend or terminate the program at any time.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ1G4Q59.USD","LKFT","LU1732800096.USD","LU0006306889.USD","LU1363072403.SGD","LU1989772923.USD","LU1074936037.SGD","BK4588","LU0557290698.USD","LU0528227936.USD","LU2357305700.SGD","BK4504","LU1064131342.USD","BK4516","LU1244550577.SGD","LU1732799900.SGD","LU1791710582.SGD","LU0158827948.USD","LU0971096721.USD","LU2264538146.SGD","LU0320765646.SGD","LU1668664300.SGD","BK4581","LU0912757837.SGD","LU0390134368.USD","LU0106261372.USD","LU1720051017.SGD","BK4534","LU2023251221.USD","LU2111349929.HKD","BK4585","LU1244550494.USD","LU2271345857.HKD","LU0234570918.USD","IE00BKVL7J92.USD","LU2089283258.USD","LU2133065610.SGD","LU1548497426.USD","LU1988902786.USD","LU0106831901.USD","LU0098860793.USD","LU0210528500.USD","LU0158827781.USD","LU2089284900.SGD","LU0053666078.USD","BK4127","LU0225283273.USD","LU1162221912.USD","LU0795875086.SGD","LU2347655156.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642975724","title":"Lakefront Biotherapeutics announces EUR 50M share repurchase program","url":"https://stock-news.laohu8.com/highlight/detail?id=2642975724","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642975724?lang=en_us&edition=fundamental","pubTime":"2026-06-10 04:13","pubTimestamp":1781036036,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics (LKFT) announced the launch of a share repurchase program, under which the company may repurchase ordinary shares for an ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakefront-biotherapeutics-announces-eur-50m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakefront-biotherapeutics-announces-eur-50m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642311664","title":"Lakefront Biotherapeutics Names Eric Hedrick as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642311664","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642311664?lang=en_us&edition=fundamental","pubTime":"2026-06-09 04:19","pubTimestamp":1780949978,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics  said late Monday it named Eric Hedrick as chief medical officer.Hedrick most recently served as clinical evaluation lead for new pipeline opportunities at the company, according to a statement.Hedrick will report to CEO Henry Gosebruch and join its management committee, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LKFT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635443167","title":"Dermatomyositis Trial Update Sets Context For LKFT’s Autoimmune Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635443167","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635443167?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:30","pubTimestamp":1778776248,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics ($LKFT) announced an update on their ongoing clinical study. Lakefront Biotherapeutics (LKFT) investors are watching a ke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermatomyositis-trial-update-sets-context-for-lkfts-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermatomyositis-trial-update-sets-context-for-lkfts-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LKFT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635357744","title":"Lakefront Biotherapeutics Spotlight: Completed Phase 2 Lupus Study Sets Stage for Key Data Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2635357744","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635357744?lang=en_us&edition=fundamental","pubTime":"2026-05-15 00:30","pubTimestamp":1778776229,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics ($LKFT) announced an update on their ongoing clinical study. Lakefront Biotherapeutics (LKFT) has highlighted a completed...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lakefront-biotherapeutics-spotlight-completed-phase-2-lupus-study-sets-stage-for-key-data-catalyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lakefront-biotherapeutics-spotlight-completed-phase-2-lupus-study-sets-stage-for-key-data-catalyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4139","LKFT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634465017","title":"Two new option listings and five option delistings on May 8th","url":"https://stock-news.laohu8.com/highlight/detail?id=2634465017","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634465017?lang=en_us&edition=fundamental","pubTime":"2026-05-09 01:14","pubTimestamp":1778260458,"startTime":"0","endTime":"0","summary":"New option listings for May 8th include Exp World Holdings, Inc. (AGNT) and Lakefront Biotherapeutics (LKFT). Option delistings effective May 8th i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-five-option-delistings-on-may-8th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/two-new-option-listings-and-five-option-delistings-on-may-8th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LKFT","AGNT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118595","title":"Galapagos NV reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633118595?lang=en_us&edition=fundamental","pubTime":"2026-05-07 15:29","pubTimestamp":1778138969,"startTime":"0","endTime":"0","summary":"Galapagos NV reports results for the quarter ended March 31 - Earnings SummaryGalapagos NV GLPG.OQ reported quarterly adjusted earnings of 11.87 per share for the quarter ended March 31, lower than th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLPG","LKFT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633159917","title":"Galapagos Q1 EPS US$0.25 Beats US$(1.27) Estimate, Sales US$7.589M Miss US$16.040M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633159917","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633159917?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:03","pubTimestamp":1778097836,"startTime":"0","endTime":"0","summary":"Galapagos (NASDAQ:GLPG) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $(1.27) by 119.69 percent. This is a 110.12 percent increase over losses of $(2.47) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52342402/galapagos-q1-eps-us-0-25-beats-us-1-27-estimate-sales-us-7-589m-miss-us-16-040m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Galapagos Q1 EPS US$0.25 Beats US$(1.27) Estimate, Sales US$7.589M Miss US$16.040M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LKFT","GLPG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}